Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

General Oncology

Request full access

General Oncology is developing innovative drug therapies for cancers

Brookline, United StatesFounded 2015Biotech & Life Sciences

About General Oncology

General Oncology is a pioneering biopharmaceutical company focused on developing innovative drug therapies for various types of cancer, including solid metastatic cancers and cancers of the blood. The company aims to create treatments that are effective yet exhibit low toxicity to patients, thereby improving their quality of life during treatment.

General Oncology operates in the highly specialized oncology market, serving patients who are battling advanced stages of cancer. The company is currently sponsoring a clinical trial, Clinical Trial GO 1, which is investigating a treatment for BRCA-related metastatic pancreatic cancer. This treatment involves a combination of chemotherapy drugs—melphalan, BCNU, vitamin B12b, and vitamin C—along with two stem cell transplants to counteract bone marrow suppression. The trial is in Phase 1 and is open for enrollment.

The business model of General Oncology revolves around the research, development, and clinical testing of novel cancer treatments. Revenue is primarily generated through partnerships, grants, and eventually, the commercialization of successful therapies. By focusing on innovative solutions and clinical trials, General Oncology aims to bring new, effective treatments to market, addressing unmet medical needs in oncology.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2015
Headquarters
Brookline, United States
Employees
8
Open positions
1
Dealroom signal
52.0/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotech & Life Sciences, Oncology, Drug Development, Stem Cells, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VCEquity / VC Nov 2021 $2.3M $9.2M Undisclosed —
EARLY VC✓Equity / VC Sep 2017 $35M $139M Undisclosed ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

General Oncology website traffic

Latest recorded traffic for General Oncology is 310 monthly website visits, down 42.6% over the last three months. General Oncology's team grew 14.3% over the past year.

Latest monthly visits310 3-month web change-42.6% 1-year team growth+14.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom
1 distinct opening shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

General Oncology in the Brookline ecosystem

Live from Dealroom

The General Oncology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about General Oncology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See General Oncology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.